You are here: Industry Insights > Roche

News List

Roche Receives FDA Approval for Complementary PD-L1 (SP263) Biomarker Test in Urothelial Carcinoma americanpharmaceuticalreview
May 09, 2017
Roche announced approval of the Ventana PD-L1 (SP263) Assay by the US Food and Drug Administration (FDA) as a complementary diagnostic to provide PD-L1 status for patients with locally advanced or metastatic urothelial carcinoma (mUC).
FDA approves Roche’s high-volume immunoassay europeanpharmaceuticalreview
May 05, 2017
Roche’s new, dedicated high-volume testing immunoassay solution for the cobas 8000 modular analyser series, the cobas e 801 module, has received 510(k) clearance from the US Food and Drug Administration (FDA).
FDA clears Roche High-Volume Immunoassay Lab Testing Solution to Support Critical Medical Treatment americanpharmaceuticalreview
May 03, 2017
Roche announced its new, high-volume testing immunoassay solution for the cobas 8000 modular analyzer series, the cobas e 801 module, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and prima worldpharmanews
April 28, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programmes will be presented during the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, Massachusetts.
Financial Report: Roche contractpharma
April 28, 2017
Pharmaceuticals sales up 3% in the quarter
CCI orders detailed probe against pharma major Roche financialexpress
April 27, 2017
The regulators decision has come on a complaint filed by drug makers Biocon and Mylan Pharmaceuticals.
Roche’s bags new US approvals for Tecentriq, Lucentis pharmatimes
April 19, 2017
The US Food and Drug Administration has expanded the approval of Roche’s Tecentriq so that it can be used to treat a wider range of patients with bladder cancer.
Roche Launches Antibody Test to Aid in Diagnosis of Challenging Prostate Cancer Cases americanpharmaceuticalreview
April 14, 2017
Roche has announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis.
Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer worldpharmanews
April 11, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global, randomised phase III ALEX study met its primary endpoint and showed that Alecensa® (alectinib)
FDA approves Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple worldpharmanews
March 30, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page